Heather L Forbes1, Thomas M Polasek2. 1. Department of Pharmacy, Repatriation General Hospital, Daw Park, South Australia, 5041, Australia. 2. Department of Clinical Pharmacology, Flinders University School of Medicine, Bedford Park, South Australia 5042, and d3 Medicine, a Certara company, Parkville, Victoria, 3052 Australia.
Abstract
BACKGROUND: To determine the prevalence and nature of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in elderly hospitalized patients. METHODS: This was a retrospective observational study. Inclusion criteria were: aged over 65 years; taking apixaban, rivaroxaban or dabigatran; and admitted to the Repatriation General Hospital between April 2014 and July 2015. A list of clinically relevant 'perpetrator' drugs was compiled from product information, the Australian Medicines Handbook, the Australian National Prescribing Service resources, and local health network guidelines. The prevalence and nature of potential DDIs with DOACs was determined by comparing inpatient drug charts with the list of perpetrator drugs. RESULTS: There were 122 patients in the study with a mean age of 82 years. Most patients had nonvalvular atrial fibrillation and were taking DOACs to prevent thrombotic stroke (83%). Overall, 45 patients (37%) had a total of 54 potential DDIs. Thirty-five patients had potential pharmacodynamic DDIs with antidepressants, nonsteroidal anti-inflammatory drugs and antiplatelets (35/122, 29%). Nineteen patients had potential pharmacokinetic DDIs (19/122, 16%). Of these, 68% (13/19) were taking drugs that increase DOAC plasma concentrations (amiodarone, erythromycin, diltiazem or verapamil) and 32% (6/19) were taking drugs that decrease DOAC plasma concentrations (carbamazepine, primidone or phenytoin). There were no cases of patients taking contraindicated interacting drugs. DISCUSSION: Potential DDIs with DOACs in elderly hospital inpatients are relatively common, particularly interactions that may increase the risk of bleeding. The risk-benefit ratio of DOACs in elderly patients on polypharmacy should always be carefully considered.
BACKGROUND: To determine the prevalence and nature of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in elderly hospitalized patients. METHODS: This was a retrospective observational study. Inclusion criteria were: aged over 65 years; taking apixaban, rivaroxaban or dabigatran; and admitted to the Repatriation General Hospital between April 2014 and July 2015. A list of clinically relevant 'perpetrator' drugs was compiled from product information, the Australian Medicines Handbook, the Australian National Prescribing Service resources, and local health network guidelines. The prevalence and nature of potential DDIs with DOACs was determined by comparing inpatient drug charts with the list of perpetrator drugs. RESULTS: There were 122 patients in the study with a mean age of 82 years. Most patients had nonvalvular atrial fibrillation and were taking DOACs to prevent thrombotic stroke (83%). Overall, 45 patients (37%) had a total of 54 potential DDIs. Thirty-five patients had potential pharmacodynamic DDIs with antidepressants, nonsteroidal anti-inflammatory drugs and antiplatelets (35/122, 29%). Nineteen patients had potential pharmacokinetic DDIs (19/122, 16%). Of these, 68% (13/19) were taking drugs that increase DOAC plasma concentrations (amiodarone, erythromycin, diltiazem or verapamil) and 32% (6/19) were taking drugs that decrease DOAC plasma concentrations (carbamazepine, primidone or phenytoin). There were no cases of patients taking contraindicated interacting drugs. DISCUSSION: Potential DDIs with DOACs in elderly hospital inpatients are relatively common, particularly interactions that may increase the risk of bleeding. The risk-benefit ratio of DOACs in elderly patients on polypharmacy should always be carefully considered.
Authors: Nicole Hager; Jennifer Bolt; Lori Albers; Wladyslaw Wojcik; Patrick Duffy; William Semchuk Journal: Can J Cardiol Date: 2016-10-28 Impact factor: 5.223
Authors: Antonio L Dans; Stuart J Connolly; Lars Wallentin; Sean Yang; Juliet Nakamya; Martina Brueckmann; Michael Ezekowitz; Jonas Oldgren; John W Eikelboom; Paul A Reilly; Salim Yusuf Journal: Circulation Date: 2012-12-27 Impact factor: 29.690
Authors: Jonathan P Piccini; Anne S Hellkamp; Jeffrey B Washam; Richard C Becker; Günter Breithardt; Scott D Berkowitz; Jonathan L Halperin; Graeme J Hankey; Werner Hacke; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Keith A A Fox; Manesh R Patel Journal: Circulation Date: 2015-12-16 Impact factor: 29.690
Authors: Greg Flaker; Renato D Lopes; Elaine Hylek; Daniel M Wojdyla; Laine Thomas; Sana M Al-Khatib; Renee M Sullivan; Stefan H Hohnloser; David Garcia; Michael Hanna; John Amerena; Veli-Pekka Harjola; Paul Dorian; Alvaro Avezum; Matyas Keltai; Lars Wallentin; Christopher B Granger Journal: J Am Coll Cardiol Date: 2014-10-14 Impact factor: 24.094
Authors: Benjamin A Steinberg; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan L Halperin; Günter Breithardt; Rod Passman; Graeme J Hankey; Manesh R Patel; Richard C Becker; Daniel E Singer; Werner Hacke; Scott D Berkowitz; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Jonathan P Piccini Journal: Heart Rhythm Date: 2014-05-13 Impact factor: 6.343
Authors: Jeroen Jaspers Focks; Marc A Brouwer; Daniel M Wojdyla; Laine Thomas; Renato D Lopes; Jeffrey B Washam; Fernando Lanas; Denis Xavier; Steen Husted; Lars Wallentin; John H Alexander; Christopher B Granger; Freek W A Verheugt Journal: BMJ Date: 2016-06-15
Authors: A John Camm; Pierre Amarenco; Sylvia Haas; Susanne Hess; Paulus Kirchhof; Silvia Kuhls; Martin van Eickels; Alexander G G Turpie Journal: Eur Heart J Date: 2015-09-01 Impact factor: 29.983
Authors: Hisham A Badreldin; Jahad Alghamdi; Omar Alshaya; Abdulmajeed Alshehri; Lamya Alreshoud; Renad Altoukhi; Senthilvel Vasudevan; Wesam W Ismail; Mohamed Salih Aziz Mohamed Journal: Int J Gen Med Date: 2020-07-22
Authors: Florentino Lupercio; Shaun Giancaterino; Pedro Arturo Villablanca; Frederick Han; Kurt Hoffmayer; Gordon Ho; Farshad Raissi; David Krummen; Ulrika Birgersdotter-Green; Gregory Feld; Ryan Reeves; Ehtisham Mahmud; Jonathan C Hsu Journal: Heart Date: 2020-02-07 Impact factor: 5.994
Authors: Galit H Frydman; Felix Ellett; Elizabeth M Van Cott; Douglas Hayden; Maulik Majmudar; Charles R Vanderburg; Haley Dalzell; Divya L Padmanabhan; Nick Davis; Julianne Jorgensen; Mehmet Toner; James G Fox; Ronald G Tompkins Journal: Crit Care Explor Date: 2019-08-20